Development of CPAP Overlay Interfaces for Efficient Administration of Aerosol Surfactant Therapy to Preterm Infants

被引:1
|
作者
Jubaer, Hasan [1 ]
Strickler, Sarah [1 ]
Farkas, Dale [1 ]
Dalton, Caleb [2 ]
Momin, Mohammad A. M. [2 ]
Dodson, Kelley M. [3 ]
Hindle, Michael [2 ]
Longest, Worth [1 ,2 ]
机构
[1] Virginia Commonwealth Univ, Dept Mech & Nucl Engn, Richmond, VA 23284 USA
[2] Virginia Commonwealth Univ, Dept Pharmaceut, Richmond, VA 23284 USA
[3] Virginia Commonwealth Univ, Dept Otolaryngol, Richmond, VA USA
来源
AAPS PHARMSCITECH | 2025年 / 26卷 / 01期
基金
比尔及梅琳达.盖茨基金会;
关键词
CPAP interface; CFD; pharmaceutical aerosol delivery; preterm infants; surfactant aerosol therapy; POSITIVE AIRWAY PRESSURE; IN-VITRO EVALUATION; DRY POWDER INHALER; FLOW NASAL CANNULA; REPLACEMENT THERAPY; PARTICLE DEPOSITION; EXPIRATORY PRESSURE; BREATHING PATTERNS; NEWBORN; DELIVERY;
D O I
10.1208/s12249-024-02987-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The administration of surfactant aerosol therapy to preterm infants receiving continuous positive airway pressure (CPAP) respiratory support is highly challenging due to small flow passages, relatively high ventilation flow rates, rapid breathing and small inhalation volumes. To overcome these challenges, the objective of this study was to implement a validated computational fluid dynamics (CFD) model and develop an overlay nasal prong interface design for use with CPAP respiratory support that enables high efficiency powder aerosol delivery to the lungs of preterm infants when needed (i.e., on-demand) and can remain in place without increasing the work of breathing compared with a baseline CPAP interface. Realistic in vitro experiments were first conducted to generate baseline validation data, and then the CFD model, once validated, was used to explore key design parameters across a range of preterm infant nose-throat geometries and aerosol delivery conditions. The most important factors for efficient aerosol delivery were shown to be (i) maintaining the aerosol delivery flow rate below the tracheal flow rate (to minimize CPAP line loss) and (ii) concentrating the aerosol within the first portion of the inhalation waveform. An optimized design was shown to deliver approximately 37-60% of the nominal dose through the system and to the lungs with low intersubject variability (1050-2200 g infants) across two modes of device actuation (automated and manual) with room for further improvement. Ergonomic curvatures and streamlining of the prong geometries were also found to reduce work of breathing and flow resistance compared with a commercial alternative.
引用
收藏
页数:25
相关论文
共 50 条
  • [1] Surfactant Administration in Preterm Infants: Drug Development Opportunities
    Taylor, Genevieve
    Jackson, Wesley
    Hornik, Christoph P.
    Koss, Alec
    Mantena, Sreekar
    Hornsley, Kenya
    Gattis, Blair
    Kudumu-Clavell, Menefese
    Clark, Reese
    Smith, P. Brian
    Laughon, Matthew M.
    JOURNAL OF PEDIATRICS, 2019, 208 : 163 - 168
  • [2] Predictors of CPAP failure after less-invasive surfactant administration in preterm infants
    Alsina-Casanova, Miguel
    Brito, Nerea
    Balcells-Esponera, Carla
    Herranz-Barbero, Ana
    Teresa-Palacio, Marta
    Soler-Garcia, Aleix
    Agusti, Carmen
    Brullas, Guillem
    Clotet, Jordi
    Carrasco, Cristina
    Salvia, Dolors
    Aldecoa-Bilbao, Victoria
    FRONTIERS IN PEDIATRICS, 2024, 12
  • [3] SURFACTANT THERAPY IN INFANTS MANAGED WITH CPAP
    ALBA, J
    AGARWAL, R
    HIATT, M
    HEGYI, T
    CLINICAL RESEARCH, 1992, 40 (03): : A660 - A660
  • [4] EFFICACY OF SURFACTANT THERAPY IN INFANTS MANAGED WITH CPAP
    ALBA, J
    AGARWAL, R
    HEGYI, T
    HIATT, IM
    PEDIATRIC PULMONOLOGY, 1995, 20 (03) : 172 - 176
  • [5] Early CPAP versus Surfactant in Extremely Preterm Infants.
    Finer, Neil N.
    Carlo, Waldemar A.
    Walsh, Michele C.
    Rich, Wade
    Gantz, Marie G.
    Laptook, Abbot R.
    Yoder, Bradley A.
    Faix, Roger G.
    Das, Abhik
    Poole, W. Kenneth
    Donovan, Edward F.
    Newman, Nancy S.
    Ambalavanan, Namasivayam
    Frantz, Ivan D., III
    Buchter, Susie
    Sanchez, Pablo J.
    Kennedy, Kathleen A.
    Laroia, Nirupama
    Poindexter, Brenda B.
    Cotten, C. Michael
    Van Meurs, Krisa P.
    Duara, Shahnaz
    Narendran, Vivek
    Sood, Beena G.
    O'Shea, T. Michael
    Bell, Edward F.
    Bhandari, Vineet
    Watterberg, Kristi L.
    Higgins, Rosemary D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (21): : 1970 - 1979
  • [6] A new method of surfactant administration in preterm infants
    Cools, Filip
    LANCET, 2011, 378 (9803): : 1607 - 1608
  • [7] Surfactant therapy in late preterm infants
    Yurdakok, Murat
    JOURNAL OF PEDIATRIC AND NEONATAL INDIVIDUALIZED MEDICINE, 2013, 2 (02):
  • [8] Nasal CPAP versus mechanical ventilation in 28 to 32-week preterm infants with early surfactant administration
    Alfonso Perez, Luis
    Marcela Gonzalez, Diana
    de Jesus Alvarez, Karen Margarita
    Alfonso Diaz-Martinez, Luis
    BIOMEDICA, 2014, 34 (04): : 612 - 623
  • [9] Endogenous Surfactant Production in Preterm Infants Is Not Supressed By Exogenous Surfactant Administration
    Jan-Erik H Bunt
    Luc J I Zimmermann
    Jack Tauladan
    Annemieke De Raad
    Darcos Wattimena
    Pieter J J Sauer
    Virgilio P Carnielli
    Pediatric Research, 1997, 42 (3) : 414 - 414
  • [10] SURFACTANT ADMINISTRATION CAUSES ACUTE HYPERCAPNIA IN PRETERM INFANTS
    KHASHABA, MT
    SHENKER, N
    MARTIN, RJ
    PEDIATRIC RESEARCH, 1991, 29 (04) : A220 - A220